CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Although the study did not meet its primary end point, the results of secondary analyses suggested a progression-free survival benefit with durvalumab plus olaparib in patients whose tumors harbor mutations in homologous recombination repair genes.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
